里瓦罗克萨班在患有腹腔大动脉动脉瘤和高敏感性C反应蛋白升高 (BANBOO) 的患者中:随机对照试验的研究方案
Jingyuan Li1,2, Sicong Ma2, Xiu Jia2
1College of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, Liaoning, China.
Trials
|June 19, 2023
概括
这项研究调查了里瓦罗克萨班是否可以减缓腹腔大动脉瘤 (AAA) 在患有高敏感性C反应蛋白 (hs-CRP) 升高的患者中进展. 在BANBOO试验中,比较了里瓦洛克萨班和阿司匹林,在六个月内评估了AAA大小和hs-CRP水平.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 生物标志物 生物标志物
背景情况:
- 腹腔大动脉瘤 (AAA) 是一种危及生命的疾病,其特点是大动脉扩张和破裂风险.
- 目前对缺乏外科治疗迹象的小AAA的药物治疗仍然存在争议.
- 高灵敏度C反应蛋白 (hs-CRP) 是AAA的潜在生物标志物,而里瓦洛克萨班表现出与AAA相关的抗炎特性.
研究的目的:
- 为了研究里瓦罗克萨班在控制腹腔大动脉瘤 (AAA) 进展的疗效,在患有高hs-CRP.患者.
- 作为主要终点,评估里瓦罗克萨班对血清hs-CRP水平的影响.
- 评估二次结果,包括AAA成像参数,主要心血管和脑血管不良事件 (MACCE) 和其他实验室标记.
主要方法:
- 一个前性的,开放的,随机对照试验 (BANBOO试验),涉及60名受试者.
- 参与者被随机分配 (1:1) 接受六个月里瓦洛克萨班或阿司匹林.
- 主要结局:血清hs-CRP水平在6个月. 其次性结局:AAA直径,壁血栓厚度,动脉瘤长度,MACCE,热素T,互白素-6,D-二次体和凝血功能.
主要成果:
- 班布 (BANBOO) 试验提供了对利瓦罗克萨班对高hs-CRP患者AAA进展的影响的首次调查.
- 该研究评估了AAA大小,hs-CRP水平的变化以及主要心血管和脑血管不良事件的发生率.
结论:
- 班布 (BANBOO) 试验代表了管理小腹动脉动脉瘤 (AAA) 的新方法.
- 这项研究是首次测试里瓦罗克萨班对AAA进展在hs-CRP升高的患者的影响.
- 结果可能会为AAA管理的未来治疗策略提供信息.
更多相关视频
相关概念视频
Aneurysm II: Clinical Manifestations and Diagnostic Studies
11
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
11
Acute Coronary Syndrome III: Diagnostic Studies
11
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
11
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
127
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
127
Aortic Regurgitation III: Medical Management
26
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
26
Aneurysm III: Interprofessional Care
12
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
12


